News
04-11-2013, 01:01 AM
Pfizer Inc. announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the United States Food and Drug Administration for the potential treatment of patients with breast cancer.
More... (http://www.news-medical.net/news/20130411/Pfizers-breast-cancer-compound-wins-FDAs-Breakthrough-Therapy-designation.aspx)
More... (http://www.news-medical.net/news/20130411/Pfizers-breast-cancer-compound-wins-FDAs-Breakthrough-Therapy-designation.aspx)